Literature DB >> 9220349

Detection and cellular localization of heparin-binding epidermal growth factor-like growth factor mRNA and protein in human atherosclerotic tissue.

T J Reape1, V J Wilson, J M Kanczler, J P Ward, K G Burnand, C R Thomas.   

Abstract

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epidermal growth factor family which binds to and activates the epidermal growth factor (EGF) receptor. HB-EGF mRNA is expressed by monocytes and vascular smooth muscle cells (VSMC) in culture, and has been shown to be a potent VSMC mitogen in vitro. The aim of this study was to screen normal and human atherosclerotic arteries and SMC cultured from these arteries for expression of HB-EGF, and to determine its cellular localization in human lesions. Using the highly sensitive technique of reverse transcription polymerase chain reaction (RT-PCR), we screened biopsies taken from normal human vessel walls and atherosclerotic tissue, for expression of HB-EGF mRNA. Northern blotting and RT-PCR were employed to determine levels of HB-EGF gene expression in SMC, cultured from normal and atherosclerotic arteries. Cellular localization of mRNA and protein, within human atherosclerotic plaques, was assessed using in situ hybridization with 35S labelled riboprobes, and immunohistochemistry with polyclonal antibodies specific for human HB-EGF. HB-EGF mRNA was found to be expressed in human atherosclerotic lesions and in VSMC cultured from these lesions. Expression of HB-EGF could not be detected in quiescent aortic VSMC using Northern blotting, but was highly up-regulated in these cells after treatment with basic fibroblast growth factor (bFGF) for 24 h. Although HB-EGF mRNA was detected in all vascular tissue examined using RT-PCR, in situ hybridization and immunohistochemistry revealed expression of HB-EGF in small portions of diseased arteries only. Immunohistochemistry showed strong staining for macrophages in all areas of HB-EGF expression. No association of HB-EGF with SMC was observed in any of the specimens examined. In conclusion, HB-EGF, a potent mitogen for VSMC, is expressed by macrophages in human.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220349     DOI: 10.1006/jmcc.1997.0399

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  9 in total

1.  Metalloproteinase processing of HBEGF is a proximal event in the response of human aortic endothelial cells to oxidized phospholipids.

Authors:  Sangderk Lee; James R Springstead; Brian W Parks; Casey E Romanoski; Roland Palvolgyi; Tiffany Ho; Phuc Nguyen; Aldons J Lusis; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-08       Impact factor: 8.311

Review 2.  Role of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Oxidative Stress-Associated Metabolic Diseases.

Authors:  Seonwook Kim; Venkateswaran Subramanian; Ahmed Abdel-Latif; Sangderk Lee
Journal:  Metab Syndr Relat Disord       Date:  2020-02-20       Impact factor: 1.894

3.  Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis.

Authors:  S Kim; M J Graham; R G Lee; L Yang; S Kim; V Subramanian; J D Layne; L Cai; R E Temel; D Shih; A J Lusis; J A Berliner; S Lee
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-01-09       Impact factor: 4.222

4.  Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit.

Authors:  Shahida Shafi; David Lamb; Helmout Modjtahedi; Gordon Ferns
Journal:  Int J Exp Pathol       Date:  2009-12-11       Impact factor: 1.925

5.  Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.

Authors:  Andrew M Bakken; Clinton D Protack; Elisa Roztocil; Suzanne M Nicholl; Mark G Davies
Journal:  J Vasc Surg       Date:  2009-05       Impact factor: 4.268

6.  Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent.

Authors:  Elisa Roztocil; Suzanne M Nicholl; Mark G Davies
Journal:  Surgery       Date:  2008-05-27       Impact factor: 3.982

7.  Targeting hepatic heparin-binding EGF-like growth factor (HB-EGF) induces anti-hyperlipidemia leading to reduction of angiotensin II-induced aneurysm development.

Authors:  Seonwook Kim; Lihua Yang; Seongu Kim; Richard G Lee; Mark J Graham; Judith A Berliner; Aldons J Lusis; Lei Cai; Ryan E Temel; Debra L Rateri; Sangderk Lee
Journal:  PLoS One       Date:  2017-08-09       Impact factor: 3.240

8.  High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis.

Authors:  Hua Jiang; Wenwei Liu; Yongshen Liu; Fengsheng Cao
Journal:  Anatol J Cardiol       Date:  2015-03-05       Impact factor: 1.596

9.  Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case-control study in China.

Authors:  Hua Jiang; Hongmei Zhang; Ying Yang; Xuezhou Yang
Journal:  BMJ Open       Date:  2020-11-06       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.